Your session is about to expire
← Back to Search
NRX 195183 for Acute Promyelocytic Leukemia
Study Summary
This trial is testing a new drug to treat people with a certain type of leukemia who have relapsed or who haven't responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition worsened or didn't tolerate previous treatments including ATRA, chemotherapy, or arsenic trioxide.I have AML that is not the APL subtype.I do not have any illnesses that limit my life expectancy to 6 months.I am HIV positive or have AIDS.I do not have severe heart problems like recent heart attacks or uncontrolled heart failure.My leukemia has a specific genetic feature confirmed by tests.I am not pregnant or nursing and will use birth control during treatment.I am 18 years old or older.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the risks associated with NRX 195183 Soft Gelatin Capsule?
"NRX 195183 Soft Gelatin Capsule is being assessed as a potential new medication, so it received a score of 2. This is because while there is data supporting its safety, there is none yet backing up its efficacy."
Could you tell me how many people are enrolled in this experiment?
"Presently, this study is not seeking any more participants. It was originally posted on April 1st, 2008 and last updated on May 9th, 2008. However, there are 1462 other trials for leukemia patients and 5 for NRX 195183 Soft Gelatin Capsule that are still looking for individuals to enroll."
To your knowledge, does a similar trial exist?
"NRX 195183 Soft Gelatin Capsule has a long research history, with the first study being conducted in 2008. The Phase 2 drug approval was received after the initial 65-person trial that was sponsored by NuRx Pharmaceuticals, Inc. Now, 5 live studies are ongoing across 6 cities and 1 nation."
Could you please share any similar research to NRX 195183 Soft Gelatin Capsule?
"As of now, there are 5 ongoing clinical trials for NRX 195183 Soft Gelatin Capsule with 1 in Phase 3. Even though a plurality of the research is based in Seattle, 8 different locations are running these sorts of studies."
Are new participants being sought for this trial?
"According to the listing on clinicaltrials.gov, this study is no longer recruiting patients for participation. The trial was first posted on April 1st, 2008 and was last updated on May 9th, 2008. There are many other trials (1467 at present) that may be a better match for individuals looking to get involved in research studies."
Share this study with friends
Copy Link
Messenger